First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors
dc.contributor.author | Ameratunga, M | |
dc.contributor.author | Harvey, RD | |
dc.contributor.author | Mau-Sorensen, M | |
dc.contributor.author | Thistlethwaite, Fiona C | |
dc.contributor.author | Forssmann, U | |
dc.contributor.author | Gupta, M | |
dc.contributor.author | Johannsdottir, H | |
dc.contributor.author | Ramirez-Andersen, T | |
dc.contributor.author | Bohlbro, ML | |
dc.contributor.author | Losic, N | |
dc.contributor.author | Ervin-Haynes, AL | |
dc.contributor.author | Lopez, JS | |
dc.contributor.author | Vergote, I | |
dc.date.accessioned | 2019-11-19T16:01:03Z | |
dc.date.available | 2019-11-19T16:01:03Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Ameratunga M, Harvey RD, Mau-S�rensen M, Thistlethwaite F, Forssmann U, Gupta M, et al. First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors. J Clin Oncol. 2019;37(15_suppl):2525-. | en |
dc.identifier.doi | 10.1200/JCO.2019.37.15_suppl.2525 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622435 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1200/JCO.2019.37.15_suppl.2525 | en |
dc.title | First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | The Alfred Hospital, Melbourne, Australia | en |
dc.identifier.journal | Journal of Clinical Oncology | en |